CN103222958A - Anticoccidial adprin dry suspension and preparation method thereof - Google Patents
Anticoccidial adprin dry suspension and preparation method thereof Download PDFInfo
- Publication number
- CN103222958A CN103222958A CN2013101667592A CN201310166759A CN103222958A CN 103222958 A CN103222958 A CN 103222958A CN 2013101667592 A CN2013101667592 A CN 2013101667592A CN 201310166759 A CN201310166759 A CN 201310166759A CN 103222958 A CN103222958 A CN 103222958A
- Authority
- CN
- China
- Prior art keywords
- dry suspension
- adprin
- surfactant
- suspension
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to the veterinary medicine field, especially relates to chicken coccidiosis control, and specifically relates to an adprin dry suspension and a preparation method thereof. The water-soluble adprin dry suspension is prepared through carrying out fusion clathration of water-insoluble adprin, and uniformly mixing with auxiliary materials comprising a suspension aid and a surfactant. The adprin dry suspension has the characteristics of simple preparation method, stable quality, good suspension effect and the like. Compared with a premix agent and present adprin oral liquid preparations, the adprin dry suspension has the advantages of use convenience, small irritation, good palatability and the like.
Description
Technical field
The present invention relates to field of veterinary, the particularly control of chicken coccidiosis, the definite a kind of A De furan quinoline dry suspension and preparation method thereof of saying so.
Background technology
Chicken coccidiosis is the chicken parasitic disease that is caused by Eimeria, and the chicken of 14-50 age in days is susceptible disease, and mortality rate is up to 30%.Be at present to the maximum a kind of parasitic disease of poultry husbandry harm.This disease pilosity in the past is born in the spring and autumn joint, and along with the development of poultry husbandry, hatching changes long-term hatching into by seasonality, humiture changes Artificial Control into by regulating naturally, and along with the modern times are cultured the expansion of scale, the increase of cultivation density, the also space of having created existence and having propagated to coccidian oocyst.This pathogen not only life cycle long, resistance is strong, general disinfecting drug is difficult to it is killed, and ill chicken still may have pathogen and excrete in several months after being ill, thereby pollutes cycle stretch-out.
At present the means of control chicken coccidiosis are still based on chemoprophylaxis, and the economic loss that whole world every year causes because of chicken coccidiosis is above 2,000,000,000 dollars.Poultry husbandry is occupied very big proportion in China's animal husbandry, and is especially in the middle part and the southern areas of China, because the weather warm moist more helps the existence and the propagation of coccidian oocyst, more serious to the harm of poultry husbandry.Along with the environmental change of raising chickens, being extensive use of of coccidiosis medicine, and use coccidiostat lack of standardization cause the drug resistance of coccidiosis to strengthen, and the infection scope of coccidiosis is also developed into into chicken and planted chicken by chickling gradually.Chicken coccidiosis infects into chicken, though majority is recessive symptom, the growth promoter that can cause breeding chicken is obstructed, and all can cause corresponding influence to rate of fertilization of survival rate, laying rate and the hatching egg of kind of chicken etc., this shows that chicken coccidiosis has become one of significant threat of current poultry husbandry.
A De furan quinoline is that it brings into play the anticoccidial effect by the purine metabolism that disturbs coccidiosis by the coccidiostat of Agricultural University Of Anhui and Agricultural University Of Nanjing's cooperation research and development.Its anticoccidial effect peak phase is the agamocytogeny of coccidiosis, and promptly effect in 1～3 day is the strongest behind coccidium infection.It is also effective to the coccidian oocyst formation stage simultaneously, and the virulence of egg capsule is reduced, and reduces appeal.Therefore, be applicable to treatment and prevent various chicken coccidiosis that A De furan quinoline belongs to the wide spectrum anticoccidial drug, and is all effective to Eimeria tenella, heap type Eimeria, Eimeria maxima and murder by poisoning Eimeria.But A De furan insoluble moiety has limited its popularization and use clinically in water, can't give full play to the anticoccidial effect of A De furan quinoline.Therefore thereby seek water solublity that a kind of suitable dosage form improves A De furan quinoline, reduce zest, improve palatability and become current urgent problem.
Summary of the invention
In order to solve above problem, the present invention is directed to the technical problem in the existing A De furan quinoline preparation, a kind of water soluble, convenient drug administration, determined curative effect for the treatment of coccidiosis of domestic fowls is provided, can realizes the dry suspension of suitability for industrialized production.This dry suspension has following advantage:
1, pre-mixing agent exists poultry morbidity back feed intake to descend when clinical use, causes influencing the picked-up of medicine, causes that therapeutic effect can not be guaranteed; Though A De furan quinoline safety coefficient is higher, it is inhomogeneous also to exist pre-mixing agent and feedstuff to mix, and local drug concentration is too high, and the phenomenon of poisoning takes place after the part chicken searches for food.In addition, after chicken morbidity, the mixing of pre-mixing agent and feedstuff is generally the manpower mode carries out, and this also consumes great amount of manpower.Dry suspension adds in the entry, at once disperse and be dispersed in the water, solve pre-mixing agent and used the problem that the mixing inequality, the ingestion of drugs concentration that are occurred are not enough, part chicken intoxicating phenomenon may take place clinically, and easy to use, saved great amount of manpower.
2, compare with oral liquid formulations, big, the relatively poor shortcoming of palatability of the acidity that dry suspension has overcome oral liquid, dry suspension has better stability in addition.
3, A De furan quinoline dry suspension preparation of the present invention is made by following formulated component:
A De furan quinoline 0.1-30 part
Suspending agent 0.05-40 part
Surfactant 0.05-30 part
Above percentage composition is based on the gross weight meter of suspensoid.
Dry suspension is characterized in that also containing in the dry suspension the pharmaceutically acceptable excipient of 0-99 part.
Dry suspension, it is characterized in that pharmaceutically acceptable excipient be selected from suspending agent, binding agent, surfactant, lubricant, the filler partly or entirely.
Its above-mentioned suspending agent includes but not limited to: any in sodium alginate, starch, xanthan gum, carbomer, polyvidone, hydroxypropyl emthylcellulose, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, cellulose acetate, the polyvinyl alcohol or more than two kinds; Any than in pyrrolidone, sodium carboxymethyl cellulose, starch, sucrose, the tragakanta of binding agent arabic gum, methylcellulose, gelatin, ethyl cellulose, polyethylene.
Its above-mentioned surfactant comprises but is not limited to: sodium lauryl sulphate, dodecyl sodium sulfate, Arlacel-20, Arlacel-60, Arlacel-80, polyoxyethylene sorbitan monooleate dehydration, the polyethenoxy sorbitan monostearate is a kind of or the combination.
Lubricant comprises and being not limited to: micropowder silica gel, Pulvis Talci.
Its above-mentioned filler includes but not limited to: anhydrous glucose, sucrose, lactose etc.
The specific embodiment
1, with the Polyethylene Glycol fusion, under fused state, add A De furan quinoline, stir, make its mix homogeneously, pulverize the back of solidifying to be cooled, crosses 200 mesh sieves.
2, get suspending agent, surfactant, binding agent, lubricant and filler and pulverize, cross 200 mesh sieves.
3, above all component substances are added in the premix machine, mixed 30 minutes, packing promptly.
4, embodiment 1
With the Macrogol 4000 heating and melting, add A De furan quinoline, stir and make dissolving, behind the cool drying, pulverize, cross 200 mesh sieves, added sodium lauryl sulphate, xanthan gum, hydroxypropyl emthylcellulose, the anhydrous glucose of 200 mesh sieves, mixing, packing.
Embodiment 2
With the polyethylene glycol 6000 heating and melting, add A De furan quinoline, stirring and dissolving behind the cool drying, is pulverized, and crosses 200 mesh sieves, adds sodium lauryl sulphate, carbopol, the anhydrous glucose of 200 mesh sieves, mixing, packing.
Embodiment 3 stability tests
Accelerated test is in order to measure this stability of formulation, and according to the requirement of " veterinary drug stability test technical specification ", the spy carries out the accelerated test of following condition, and the product of embodiment 1 and embodiment 2 is tested.Experimental condition: with two kinds of A De furan quinoline dry suspension and aqueous solution (0.51L water) sample thereof of embodiment 1 and embodiment 2
It is in 75% the calorstat with relative humidity that temperature is 40 degrees centigrade, with sampling respectively in the 1st, 2,3,6 month, and observes character respectively and measures content, and experimental result is as follows:
The dry suspension of table 1 embodiment 1 quickens to stablize experimental result
The dry suspension of table 2 embodiment 2 quickens to stablize experimental result
From the result of check, the A De furan quinoline dry suspension of embodiment 1 and embodiment 2 during accelerated stability test in, character does not all change, settling ratio illustrates that all greater than 0.9 dispersibility is fine, and content does not have to change substantially, every index all meets the requirements, and this product good stability is described.
Embodiment 4 clinical trials
1. material
A De furan quinoline pre-mixing agent, Agricultural University Of Anhui's pharmacological experiment chamber development.
Embodiment 1: A De furan quinoline dry suspension.
2. method
250 pre-mixing agents are joined in the feedstuff of 1000kg, after the stirring, the chicken that suffers from coccidiosis for 23 ages in days searches for food logotype 5 days.A De furan quinoline dry suspension 500g is dissolved in the 500L water, suffers from the chicken of coccidiosis for 23 ages in days and drinks logotype 5 days.
3. result
The therapeutic effect of table 3 pre-mixing agent and 1 pair of chicken coccidiosis of embodiment
From experimental result as can be seen, embodiment 1 compares with pre-mixing agent, and the effect of its treatment is better than pre-mixing agent, and the effect of weightening finish obviously is better than pre-mixing agent.So 1 couple of the embodiment of the A De furan quinoline of development is clinical crucial meaning is arranged.
Although the present invention describes with reference to specific embodiment, this description and not meaning that is construed as limiting the present invention.With reference to description of the invention, other distortion of the disclosed embodiments all can be expected for those skilled in the art.Therefore, such distortion can not break away from affiliated claim restricted portion and spirit.
Claims (5)
1. A De furan quinoline dry suspension, its feature with this A De furan quinoline dry suspension by weight percentage, comprise A De furan quinoline 0.1-30 part, suspending agent 0.05-40 part, surfactant 0.05-30 part.
2. according to the dry suspension of claim 1, it is characterized in that also containing in the dry suspension the pharmaceutically acceptable excipient of 0-99 part.
3. according to the dry suspension of claim 1, it is characterized in that pharmaceutically acceptable excipient be selected from suspending agent, binding agent, surfactant, lubricant, the filler partly or entirely.
4. require each dry suspension of 1-3 according to power, it is characterized in that suspending agent includes but not limited to any in Polyethylene Glycol, sodium alginate, starch, xanthan gum, carbopol, polyvidone, hydroxypropyl emthylcellulose, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, cellulose acetate, the polyvinyl alcohol or more than two kinds; Any than in pyrrolidone, sodium carboxymethyl cellulose, starch, sucrose, the tragakanta of binding agent arabic gum, methylcellulose, gelatin, ethyl cellulose, polyethylene.Surfactant comprise but be not limited to sodium lauryl sulphate, dodecyl sodium sulfate, Arlacel-20, Arlacel-60, Arlacel-80, polyoxyethylene sorbitan monooleate dehydration, the polyethenoxy sorbitan monostearate is a kind of or the combination.Lubricant comprises and is not limited to micropowder silica gel, Pulvis Talci; Filler includes but not limited to anhydrous glucose, sucrose, lactose etc.
5. according to the preparation method of the dry suspension of claim 1: with the Polyethylene Glycol fusion, under fused state, add A De furan quinoline, stir, make its mix homogeneously, pulverize the back of solidifying to be cooled, crosses 200 mesh sieves, add suspending agent, surfactant and filler again, mixing, packing is promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101667592A CN103222958A (en) | 2013-04-22 | 2013-04-22 | Anticoccidial adprin dry suspension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101667592A CN103222958A (en) | 2013-04-22 | 2013-04-22 | Anticoccidial adprin dry suspension and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103222958A true CN103222958A (en) | 2013-07-31 |
Family
ID=48833757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101667592A Pending CN103222958A (en) | 2013-04-22 | 2013-04-22 | Anticoccidial adprin dry suspension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103222958A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208026A (en) * | 2013-09-30 | 2014-12-17 | 郑州后羿制药有限公司 | Preparation method of adprin microsphere |
| CN106667898A (en) * | 2017-02-22 | 2017-05-17 | 佛山市南海东方澳龙制药有限公司 | Decoquinate preparation as well as preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450044A (en) * | 2008-12-29 | 2009-06-10 | 天津瑞普生物技术股份有限公司 | Anti-coccidium suspension agent containing nicarbazin and preparation technique thereof |
| CN102274173A (en) * | 2011-09-09 | 2011-12-14 | 广州华农大实验兽药有限公司 | Novel anticoccidial agent adprin solution and preparation method thereof |
| CN102532138A (en) * | 2012-02-17 | 2012-07-04 | 曾明华 | Synthesis method of anticoccidial drug adprin |
| CN102973504A (en) * | 2012-10-30 | 2013-03-20 | 河南牧翔动物药业有限公司 | Adprin nano-emulsion anticoccidial drug and preparation process thereof |
-
2013
- 2013-04-22 CN CN2013101667592A patent/CN103222958A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450044A (en) * | 2008-12-29 | 2009-06-10 | 天津瑞普生物技术股份有限公司 | Anti-coccidium suspension agent containing nicarbazin and preparation technique thereof |
| CN102274173A (en) * | 2011-09-09 | 2011-12-14 | 广州华农大实验兽药有限公司 | Novel anticoccidial agent adprin solution and preparation method thereof |
| CN102532138A (en) * | 2012-02-17 | 2012-07-04 | 曾明华 | Synthesis method of anticoccidial drug adprin |
| CN102973504A (en) * | 2012-10-30 | 2013-03-20 | 河南牧翔动物药业有限公司 | Adprin nano-emulsion anticoccidial drug and preparation process thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王中宝等: "阿德呋啉水溶剂治疗鸡球虫病的试验研究", 《中国兽药杂志》, vol. 46, no. 4, 31 December 2012 (2012-12-31), pages 22 - 24 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208026A (en) * | 2013-09-30 | 2014-12-17 | 郑州后羿制药有限公司 | Preparation method of adprin microsphere |
| CN106667898A (en) * | 2017-02-22 | 2017-05-17 | 佛山市南海东方澳龙制药有限公司 | Decoquinate preparation as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103054808B (en) | Tilmicosin dry suspension, method for preparing dry suspension and uses thereof | |
| CN102614129B (en) | Enrofloxacin dry suspension | |
| CN101564376B (en) | Decoquinate solid dispersoid and preparation method thereof | |
| CN101450044B (en) | Anti-coccidium suspension agent containing nicarbazin and preparation technique thereof | |
| CN103301144A (en) | Antibiotic premixing agent for inhibiting porcine reproductive and respiratory syndrome virus for livestock and preparation method thereof | |
| CN108815123A (en) | A kind of curcumin solid dispersion and its preparation method and application | |
| CN108042485B (en) | A kind of Altrenogest preparation and preparation method thereof | |
| CN102274189A (en) | Decoquinate-containing suspension formula and preparation method thereof | |
| CN104906121A (en) | Tildipirosin-containing medicinal composition | |
| CN103222958A (en) | Anticoccidial adprin dry suspension and preparation method thereof | |
| CN101606908A (en) | Decoquinate soluble powder and preparation method thereof | |
| CN101926776B (en) | Salinomycin sodium suspension as well as preparation method and application thereof | |
| CN102908313A (en) | Veterinary albendazole suspension and preparation method thereof | |
| CN107595871A (en) | Compound preparation containing ivermectin and preparation method thereof | |
| CN111388498B (en) | Spectinolincomycin hydrochloride soluble powder capable of being mutually dissolved with oil seedlings after being dissolved in water and preparation method thereof | |
| CN101559074B (en) | Coccidiostat-decoquinate dry suspension for livestock and poultry and preparation method thereof | |
| CN103006617B (en) | Decoquinate oral micro-capsule preparation and preparation process thereof | |
| CN107693532A (en) | Compound anti-parasitic preparation and preparation method thereof | |
| CN103251552B (en) | Enrofloxacin cataplasm and preparation method thereof | |
| CN103705459A (en) | Crystallized ceftiofur free acid nano-emulsion injection and preparation method thereof | |
| CN105748405A (en) | An albendazole suspension for veterinary use and a preparing method thereof | |
| CN101904858A (en) | Method for preparing coccidium-resistant suspension | |
| CN102397541A (en) | Preparation method for microencapsulated oral live vaccine of gosling plague | |
| CN102008435B (en) | Avian decoquinate oral suspension and preparation method thereof | |
| CN105878184A (en) | Altrenogest nanometer emulsion and method for preparing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130731 |